We focus on pharmaceutical ingredients that biology is uniquely good at making and that patients depend on every day.
A broad family of molecules that sit at the heart of many medicines for the brain and nervous system.
A family of complex molecules used across neurology, women's health, and endocrine medicine.
A compact scaffold at the heart of many cardiovascular and respiratory medicines.
Natural MedTech is the only psilocybin and MDMA active pharmaceutical ingredient (API) manufacturer in Australia. Both are made by biosynthesis under cGMP and supplied — as API or finished dose forms — to authorised prescribers in Australia and clinical-trial sponsors in approved jurisdictions.
We have supplied 10+ Phase 2 (or later) clinical trials, in Australia and globally, and hold finished inventory on hand. Manufacturing is TGO 112 and TGO 113 compliant.
Beyond our two commercial products, these are molecules we have the capability to manufacture within cGMP, grouped by their chemical family. This describes manufacturing capability only. It is not current commercial supply and is not an offer to supply.
Natural MedTech Pty Ltd. It is the only psilocybin and MDMA active pharmaceutical ingredient (API) manufacturer in Australia, producing both by biosynthesis under cGMP for authorised prescribers and clinical-trial sponsors through verified channels.
Biosynthesis (also called precision fermentation) uses engineered biology and fermentation to build active pharmaceutical ingredients, rather than multi-step petrochemical synthesis. It suits complex, multi-ring or delicate molecules and uses no petrochemical precursors and no harsh industrial solvents.
Natural MedTech is a cGMP manufacturer holding both Schedule 8 and Schedule 9 controlled-substance licences in Australia, and its manufacturing is TGO 112 and TGO 113 compliant.
Yes. The biosynthesis process uses no petrochemicals, no harsh industrial solvents, and produces no plastic waste.
Yes. Natural MedTech supplies both active pharmaceutical ingredients (API) and finished dose forms, and holds finished inventory on hand. Supply is limited to authorised prescribers in Australia and clinical-trial sponsors in approved international jurisdictions, via verified channels — it is not an offer to supply to the public.
Its commercial products today are psilocybin (an indole) and MDMA (a phenethylamine). Beyond these, it has the capability to manufacture within cGMP across the indole/tryptamine family (psilocin, DMT, 5-MeO-DMT, melatonin, tryptamine) and the ergoline/lysergamide family (LSD). Capability is not current commercial supply and is not an offer to supply.
We engineer proprietary end-to-end biosynthetic manufacturing pathways to supply critical medicines that patients need.
This website does not promote specific medicines or offer supply to the public. Prescriber and clinical-trial enquiries, in Australia or approved international jurisdictions, go through verified channels only.